Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2013

View Archived Issues

Eisai presents highlights of first quarter of fiscal 2013

Otsuka updates accomplishments of second quarter 2013

Novel biomarker is associated with response to anti-EGFR cancer treatment

Preclinical characterization of a GIP analogue for the treatment of diabetes

Celgene presents phase III results for nab-paclitaxel in metastatic melanoma

Grafix shows efficacy in stem cell study for diabetic foot ulcers

Reliable insulin delivery seen with Adagio inhalable insulin in phase I/II trial

A novel COX-2 inhibitor shows potential as adjuvant radiosensitizer in melanoma cell lines

Lilly's phase III trial of necitumumab in NSCLC meets primary endpoint of overall survival

Atlantic Pharmaceuticals completes pre-IND meeting with FDA for abuse-deterrent hydrocodone

Patrys discloses additional data from phase I/II trial of PAT-SM6 in MM

Trial of CPX-351 in high-risk leukemia and myelodysplastic syndrome initiated

Myelin Repair Foundation and Gencia Corporation to collaborate on multiple sclerosis therapeutics

AdvanDx launches Gram-Negative QuickFISH BC assay

GW Pharmaceuticals opens U.S. IND application for phase III Sativex program

Taisho Pharmaceutical presents new mGlu2 receptor antagonists

Sanford-Burnham and Pfizer to identify targets for treatment of diabetes

Japanese researchers patent novel agents for promoting osteogenesis

FDA approves liquid form of enalapril

Eli Lilly discloses new MGAT2 inhibitors for hypertriglyceridemia

Acasti Pharma reports data from phase II CaPre trial

Suda acquires NovaDel Pharma assets

Altor receives IND clearance to advance ALT-803 into clinical trials in melanoma

Mallinckrodt submits results from PK study requested by FDA in response to Pennsaid 2% NDA

ALN-AT3 receives orphan drug designation from the FDA

Boehringer Ingelheim enters agreement to study real-world use of oral anticoagulants

Dosing begins in phase I study of DX-2930

Cedars-Sinai begins phase I trial of Copaxone as immunization for Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...